24 February 2017
DETAILS
Full year 2016 results*
- Profit for the period attributable
to Solvay share, on an IFRS basis
was € 621 million vs € 406 million in 2015.
On an underlying basis
it grew to € 846 million versus € 768 million in 2015. - Underlying EBITDA grew 7.5% to € 2,284 million,
driven by pricing power of 5.9%
and fixed cost reduction benefits of 2.9%.
Operational excellence exceeded € 200 million,
while completion of the Cytec integration
delivered € 70 million of synergies,
well ahead of the initial plan.
There were no significant effects
from volume/mix changes.
Foreign exchange fluctuations
had a (1.9)% conversion effect.
The EBITDA margin reached a record 21%,
a notable increase from 19% in 2015. - Free cash flow was € 876 million,
up € 384 million year on year.
Continuing operations accounted for € 736 million,
an increase of € 342 million, driven by
higher EBITDA, reduced capital expenditure
and efficient working capital management. - CFROI increased to 6.3%, up 0.2 percentage point
from 6.1% pro forma in 2015 on non-restated basis. - Dividend increase proposed of 4.5%
to € 3.45 gross per share for 2016,
payable on May 16, 2017. - Net sales fell (4.7)% to € 10.9 billion, as
lower sales prices in a deflationary raw material
price environment weighed (2.3)%.
Foreign exchange fluctuations dented sales
by (1.5)%.
Volumes were stable overall.
Jean-Pierre Clamadieu
“Solvay delivered solid full-year EBITDA growth
supported by our transformation
and subsequent improvement of our customer profile.
Our pursuit of operational excellence,
swift delivery of synergies
and continued pricing momentum
have contributed strongly to our performance.
The upgrade of our portfolio has also enabled us
to significantly lower our greenhouse gas intensity.
Overall, these elements combine to enhance
our sustainable value creation
for both customers and shareholders.”
Media relations
Caroline Jacobs
+32 2 264 1530
caroline.jacobs@solvay.com
WWW.CHEMWINFO.COM BY KHUN PHICHAI